Investigation of the Discriminatory Ability of Pharmacokinetic Metrics for the Bioequivalence Assessment of PEGylated Liposomal Doxorubicin

@article{Hsu2018InvestigationOT,
  title={Investigation of the Discriminatory Ability of Pharmacokinetic Metrics for the Bioequivalence Assessment of PEGylated Liposomal Doxorubicin},
  author={Li-feng Hsu},
  journal={Pharmaceutical Research},
  year={2018},
  volume={35},
  pages={1-10}
}
The purpose of the study was to construct a population pharmacokinetic model for pegylated liposomal doxorubicin and use the final model to investigate the discrimination performance of pharmacokinetic metrics (e.g., Cmax, AUC and partial AUC) of various analytes (e.g., liposome encapsulated doxorubicin, free doxorubicin and total doxorubicin) for the identification of formulation differences by means of Monte Carlo simulations. A model was simultaneously built to characterize the concentration… CONTINUE READING
0 Citations
27 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Bioequivalence Study of Pegylated Doxorubicin Hydrochloride Liposome (PEGADRIA) and DOXIL® in Ovarian Cancer Patients: Physicochemical Characterization and Pre-clinical Studies

  • A Sm, S S.
  • J Nanosci Nanotechnol
  • 2016
1 Excerpt

Modeling in biopharmaceutics, pharmacokinetics and pharmacodynamics: homogeneous and heterogeneous approaches

  • P Macheras, A. Iliadis
  • Karalis V, editor. Modeling and simulation in…
  • 2016
2 Excerpts

Similar Papers

Loading similar papers…